1)DNA has no good reason to buy this expensive POS.
2)IDPH will have to buy another BIOTECH company. And there is risk concerning whether the management might do the same thing. They have wasted so much money on building redundant overcapacity. What on the earth will they produce???
3) Rituxan is approaching to its market saturation and Zerolin is a failure.
4) IDPH's pipeline is almost empty!! No future!! In this business, pipeline is everthing!!
To sum up, IDPH is a long-term failure. It has much higher risk than reward even at $25.
You can trade this POS like me. I have 10K shares of this POS in my short positions. I was bleeding with my AMZN short position for two weeks, but finally my patience began to pay off.
Believe it or not, I shorted more shares of AMZN at the 52 week high. Now I feel much better.
This war will cost a lot to our economy and accordingly to stock market:
A new law, Blood's law, has been born.
More blood with our troops or Iraqis => more blood on WS.